GenomeDx to Distribute Pathnostics’ Guidance UGx Test for Urinary Tract Infection and Guidance PRx Test for Prostatitis

Truckee, CA ( GenomeDx Biosciences, a leader in the field of urologic genomics, and Pathnostics, a provider of comprehensive and dynamic pathology services, announced a strategic agreement for GenomeDx’s distribution of Pathnostics’ Guidance UGx and Guidance PRx. These molecular diagnostic tests for urinary tract infections (UTIs) and prostatitis, respectively, improve upon traditional urine culture by detecting the genomic sequence of pathogens, providing a faster and more comprehensive solution for physicians and their patients. 

GenomeDx will have exclusive distribution rights for Guidance UGx and Guidance PRx in most of the US urology market, and Pathnostics will perform the testing at its CAP-accredited, CLIA-certified laboratory in Irvine, California.
“GenomeDx continues to drive the commercial adoption of genomic testing in urology through our proprietary Decipher classifier tests for prostate and bladder cancer and through strategic partnerships to expand our commercially available solutions,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “The management of UTIs and prostatitis is an area of great unmet medical need, and this partnership with Pathnostics allows us to provide a clinically superior solution to an antiquated technology in a way that is consistent with our focus on genomics and the urology market.”
David Baunoch, Ph.D., chief scientific officer of Pathnostics, commented, “UTI and prostatitis cases often consist of complex polymicrobial infections that are commonly misclassified using traditional urine culture. Guidance testing allows for pathogen identification and characterization of antibiotic resistance days earlier than culture methodologies. We believe that Guidance pathogen identification and resistance testing improves patient outcomes.” 

Dave Pauluzzi, chairman of Pathnostics, added, “Given the great commercial adoption we have had to date, with over 50,000 patients already tested, it is the right time to partner with GenomeDx to bring this technology to the broader urology community. GenomeDx is a leader in genomics in urology, and Guidance UGx and Guidance PRx are natural complements to GenomeDx’s Decipher portfolio of genomic solutions.”

Related Content:

EAU 2017: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy

EAU 2017: The diverse genomic landscape of low-risk prostate cancer